XML 93 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
SHAREHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2014
Stockholders' Equity Note [Abstract]  
SHAREHOLDERS' EQUITY
SHAREHOLDERS’ EQUITY
 
Valeant Pharmaceuticals International, Inc. Shareholders
 
 
 
 
 
Common Shares
 
Additional
Paid-In
Capital
 
Accumulated
Deficit
 
Accumulated
Other
Comprehensive
Loss
 
Valeant
Pharmaceuticals
International, Inc.
Shareholders’
Equity
 
Noncontrolling
Interest
 
Total
Equity
 
Shares
 
Amount
 
 
 
 
 
 
Balance, January 1, 2013
303.9

 
$
5,940.7

 
$
267.1

 
$
(2,371.0
)
 
$
(119.4
)
 
$
3,717.4

 
$
—

 
$
3,717.4

Issuance of common stock(1)
27.1

 
2,269.3

 
—

 
—

 
—

 
2,269.3

 
—

 
2,269.3

Common shares issued under share-based compensation plans(2)
2.5

 
64.2

 
(60.6
)
 
—

 
—

 
3.6

 
—

 
3.6

Repurchase of common shares(2)
(0.7
)
 
(14.2
)
 
—

 
(41.4
)
 
—

 
(55.6
)
 
—

 
(55.6
)
Share-based compensation
—

 
—

 
32.5

 
—

 
—

 
32.5

 
—

 
32.5

Employee withholding taxes related to share-based awards
—

 
—

 
(35.9
)
 
—

 
—

 
(35.9
)
 
—

 
(35.9
)
Tax benefits from stock options exercised
—

 
—

 
48.6

 
—

 
—

 
48.6

 
—

 
48.6

Noncontrolling interest from business combinations
—

 
—

 
—

 
—

 
—

 
—

 
113.5

 
113.5

Noncontrolling interest distributions
—

 
—

 
—

 
—

 
—

 
—

 
(2.1
)
 
(2.1
)
 
332.8

 
8,260.0

 
251.7

 
(2,412.4
)
 
(119.4
)
 
5,979.9

 
111.4

 
6,091.3

Comprehensive loss:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss (income)
—

 
—

 
—

 
(989.9
)
 
—

 
(989.9
)
 
1.3

 
(988.6
)
Other comprehensive loss
—

 
—

 
—

 
—

 
(40.9
)
 
(40.9
)
 
(0.6
)
 
(41.5
)
Total comprehensive loss
 
 
 
 
 
 
 
 
 
 
(1,030.8
)
 
0.7

 
(1,030.1
)
Balance, September 30, 2013
332.8

 
$
8,260.0

 
$
251.7

 
$
(3,402.3
)
 
$
(160.3
)
 
$
4,949.1

 
$
112.1

 
$
5,061.2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance, January 1, 2014
333.0

 
$
8,301.2

 
$
228.8

 
$
(3,278.5
)
 
$
(132.8
)
 
$
5,118.7

 
$
114.6

 
$
5,233.3

Common shares issued under share-based compensation plans
1.0

 
33.2

 
(23.6
)
 
—

 
—

 
9.6

 
—

 
9.6

Settlement of stock options
—

 
—

 
(3.1
)
 
—

 
—

 
(3.1
)
 
—

 
(3.1
)
Share-based compensation
—

 
—

 
60.6

 
—

 
—

 
60.6

 
—

 
60.6

Employee withholding taxes related to share-based awards
—

 
—

 
(38.5
)
 
—

 
—

 
(38.5
)
 
—

 
(38.5
)
Tax benefits from stock options exercised
—

 
—

 
17.1

 
—

 
—

 
17.1

 
—

 
17.1

Acquisition of noncontrolling interest
—

 
—

 
(1.1
)
 
—

 
—

 
(1.1
)
 
(2.2
)
 
(3.3
)
Noncontrolling interest distributions
—

 
—

 
—

 
—

 
—

 
—

 
(0.5
)
 
(0.5
)
 
334.0

 
8,334.4

 
240.2

 
(3,278.5
)
 
(132.8
)
 
5,163.3

 
111.9

 
5,275.2

Comprehensive loss:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss)
—

 
—

 
—

 
378.6

 
—

 
378.6

 
(0.5
)
 
378.1

Other comprehensive loss
—

 
—

 
—

 
—

 
(419.2
)
 
(419.2
)
 
(0.5
)
 
(419.7
)
Total comprehensive loss
 
 
 
 
 
 
 
 
 
 
(40.6
)
 
(1.0
)
 
(41.6
)
Balance, September 30, 2014
334.0

 
$
8,334.4

 
$
240.2

 
$
(2,899.9
)
 
$
(552.0
)
 
$
5,122.7

 
$
110.9

 
$
5,233.6


____________________________________
(1)
On June 24, 2013, the Company completed, pursuant to an Underwriting Agreement with Goldman Sachs & Co. and Goldman Sachs Canada, Inc., a public offering of 27,058,824 of its common shares, no par value, at a price of $85.00 per share, or aggregate gross proceeds of approximately $2.3 billion. In connection with the issuance of these new common shares, the Company incurred approximately $30.7 million of issuance costs, which has been reflected as reduction to the gross proceeds from the equity issuance.
(2)
During the second quarter of 2013, 225,000 common shares were repurchased by the Company pursuant to a purchase agreement with Goldman, Sachs & Co. Under this purchase program, the repurchases were made by Goldman, Sachs & Co. in compliance with Rule 10b5-1(c)(1)(i) of the Securities Exchange Act of 1934. 217,294 of these common shares were repurchased on behalf of certain members of the Company’s Board of Directors, and were subsequently transferred to such directors, in connection with the share settlement of certain deferred stock units and restricted stock units held by such directors following the termination of the applicable equity program. The remaining 7,706 common shares were repurchased on behalf of the Company pursuant to the 2012 Securities Repurchase Program (and therefore these shares are included in the 507,957 of total common shares repurchased under the 2012 Securities Repurchase Program as of September 30, 2013) and were subsequently cancelled (see note 11 titled “SECURITIES REPURCHASE PROGRAM” for further information).